KALY Beast Mode! News Out! via OTC PR WIRE --
Post# of 63696
(Total Views: 177)
Posted On: 10/29/2018 11:47:30 AM
KALY Beast Mode! News Out!
via OTC PR WIRE -- Kali, Inc. (USOTC: KALY) today announced entering into discussions with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to explore forming a joint venture company between the three to develop cannabis pharmaceutical products. Kali recently announced a letter of intent to acquire NCM Biotech, the developer and owner of a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." Separately, Puration has licensed the NCM patent for use in specific commercial applications. Nouveau has recently acquired a cannabis cultivation operation from Puration. In the joint venture, Kali would build on NCM's medical research, and Puration's commercial experience, combined with Nouveau's plans to develop a proprietary pharmaceutical grade hemp cultivar, to together develop cannabis pharmaceutical products in partnerships with established pharmaceutical development companies.
Frederick Ferri, CEO and Founder of NCM Biotech notes, "Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPH] products and candidate products."
NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.
Learn more about NCM Biotech at https://www.ncmbiotech.com/
via OTC PR WIRE -- Kali, Inc. (USOTC: KALY) today announced entering into discussions with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to explore forming a joint venture company between the three to develop cannabis pharmaceutical products. Kali recently announced a letter of intent to acquire NCM Biotech, the developer and owner of a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." Separately, Puration has licensed the NCM patent for use in specific commercial applications. Nouveau has recently acquired a cannabis cultivation operation from Puration. In the joint venture, Kali would build on NCM's medical research, and Puration's commercial experience, combined with Nouveau's plans to develop a proprietary pharmaceutical grade hemp cultivar, to together develop cannabis pharmaceutical products in partnerships with established pharmaceutical development companies.
Frederick Ferri, CEO and Founder of NCM Biotech notes, "Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPH] products and candidate products."
NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.
Learn more about NCM Biotech at https://www.ncmbiotech.com/
(0)
(0)Scroll down for more posts ▼